Earnings Releases·Oct 30, 2026, 8:03 AM ET

Aurinia Pharmaceuticals — Q3 2026 Earnings Summary

Q3 2026 total revenue rose 14% year-over-year to $83.7 million, driven by a 12% increase in LUPKYNIS net product sales to $79.4 million, while nine-month revenue grew 19% to $244.6 million.
The company raised its full-year 2026 total revenue guidance to $325 million–$330 million and narrowed net product sales guidance to $310 million–$315 million.
Nine-month net income increased 35% to $103.5 million, with diluted EPS rising 38% to $0.76, supported by a 46% increase in operating cash flow to $131.5 million.
Capital allocation included the repurchase of 5.0 million common shares for $74.9 million in the first nine months, partially offset by $35.9 million in proceeds from equity awards.
Strategic progress includes the initiation of the PRESERVE Phase 4 study for LUPKYNIS combination therapies and the commencement of clinical development for aritinercept across four autoimmune indications.